Understanding CELMoDs in Multiple Myeloma: Mechanism, Differentiation From IMiDs, and the Next-Generation Class

Dr. Joseph Mikhael welcomes the audience to the Cancer Network Training Academy program and introduces Dr. Paul Richardson and Dr. Scott Goldsmith, who bring clinical and research expertise in multiple myeloma.

Dr. Mikhael begins the scientific foundation by asking Dr. Richardson to define CELMoDs and explain how they engage the cereblon E3 ubiquitin ligase complex to promote targeted degradation of Ikaros and Aiolos, key transcription factors involved in myeloma-cell biology.